A Polygenic Risk Score Assessment Reveals More Screening Participants with Clinically Significant Prostate Cancer Than Those Who Would Be Identified with PSA or MRI By Ogkologos - April 30, 2025 624 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BARCODE1 study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR ΚΑΡΚΙΝΟΣ ΧΟΛΗΔΟΧΟΥ ΚΥΣΤΕΩΣ March 8, 2019 Five Questions With…Jae. May 19, 2022 Why haven’t we cured cancer? June 20, 2022 The Right to be Forgotten: ESMO Calls on EU Countries to... October 18, 2023 Load more HOT NEWS Potential of Molecular Profiling to Refine Surgical and Radiotherapy Decision-Making in... Resilience Isn’t About Bouncing Back Worries About Medical Bills May Worsen Health Outcomes After Cancer Diagnosis Study Adds to Debate about Screening for Melanoma
